113results about How to "No obvious toxicity" patented technology

The invention discloses a method for preparing an anti-virus molecularly imprinted polymer. The method comprises the steps of modifying dopamine nanofilm on a carrier material, then combining a target virus with the carrier material modified with the dopamine nanofilm, forming a virus-dopamine-carrier material compound, eluting the target virus from the compound, and obtaining the corresponding anti-virus molecularly imprinted polymer. According to the anti-virus molecularly imprinted polymer, imprinted holes left after the virus is eluted can be utilized, the target virus is combined in a specific mode, and the target virus is prevented from multiplication and infecting a host; the anti-virus molecularly imprinted polymer has the advantages of being good in using specificity, friendly in service environment and simple in regenerate, and a good using prospect in the biological immunity field is achieved.

The invention relates to Styrax faberi Perk leaf tea and a preparation method thereof, wherein Styrax faberi Perk leaves are leaves of Styracaceae herb Styrax faberi Perk. The preparation method of the Styrax faberi Perk leaf tea comprises the following step of: carrying out enzyme deactivation, twisting and roasting on the Styrax faberi Perk leaves to prepare a tea preparation. One or a plurality of green tea, jasmine flowers, honeysuckle or chrysanthemum can be added in the Styrax faberi Perk leaves to prepare tea beverage with better mouthfeel and more efficacies. The prepared Styrax faberi Perk leaves can be directly brewed by using boiling water with the temperature above 90 DEG C, and the ratio between tea and water is preferably 1:50 to 1:60 (namely 50 to 60mL water pre 1g tea), therefore, the brewed tea has yellow and bright tea juice, moderate thickness, and is fresh, mellow, cool and tasty. The Styrax faberi Perk leaf tea has no remarkable toxicity after toxicity testing, is safe and reliable to drink, suitable for all types of people, in particular regular smokers and drinkers and has the efficacy of cooling and removing internal heat, eliminating phlegm and diminishing inflammation, waking up the patient from unconsciousness and blooming spirit, prompting flow of qi and blood circulation, improving eyesight and clearing away heart fire, resisting bacteria, inflammation and virus and strengthening immunity.

The invention relates to a medicine composition of myricetrin or/and myricetin aglycone thereof and levodopa or of levodopa and carbidopa and an application of myricetrin or/and myricetin aglycone thereof as a synergist in preparation of a medicine used for treating Parkinson. In vitro activity determination finds that IC50 of myricetrin and myricetin inhibiting catechol-O-methyltransferase (COMT) can be a micromole-nanomole scale. Rat overall pharmacokinetic study finds that blood concentration of levodopa can be increased after myricetrin and myricetin aglycone thereof and levodopa are used jointly; and myricetrin and myricetin aglycone thereof are high in safety, no obvious toxicity is produced to main visceral organ cells of a human body, and no active intermediate is produced by virtue of metabolism activation and further no damage done to organs such as liver and kidney is initiated, so that the myricetrin and myricetin aglycone thereof have a good application prospect in adjuvant therapy of Parkinson.

The invention discloses a citrus chachiensis hortorum polymethoxylated flavonoids effective part and application thereof for treating hyperlipidaemia. The effective part is prepared from the following steps: step S1, extracting: grinding the citrus chachiensis hortorum, extracting by use of an alcohol-water solution, concentrating; step S2, removing impurities; sampling the concentrated solution obtained in the step S1 on macroporous resin, eluting and removing impurities by use of an ethanol water solution with the volume percent concentration of 40-45%, wherein the model of the macroporous resin is D101 type; and step S3, eluting: eluting the macroporous resin by use of the ethanol water solution with the volume percent concentration of 90% or more, collecting eluent, concentrating to obtain the citrus chachiensis hortorum polymethoxylated flavonoids effective part. The citrus chachiensis hortorum polymethoxylated flavonoids effective part provided by the invention can effectively lower the blood lipid level of hyperlipidaemia model mice, and is non-toxic, safe and effective, and can be used for preventing or treating hyperlipidaemia.

The invention relates to an acne removing formulation. The acne removing formulation is prepared from 1.5-4.5% of liquorice, 2-5% of root bark of white mulberries, 1-5% of chamomile, 0.5-5% of salvia miltiorrhiza, 1-5% of scutellaria baicalensis, 1.5-5% of cortex phellodendri, 1-7% of radix sophorae flavescentis, 0.5-3.5% of honeysuckle, 1.5-6% of fructus forsythiae, 1-4% of coptis chinensis, 1-3% of folium isatidis, 0.5-5% of rheum officinale, 3-5% of herba portulacae, and a plurality of solvents. The acne removing formulation has the effects of inhibiting generation of acne, removing acne marks and whitening the skin, and is remarkable in effect and fast in effect taking, acne marks are avoided after healing, relapse is avoided, grease secretion of the skin can be effectively reduced, and metabolism of epidermis cells can be effectively promoted.

The invention discloses a microtopological-structure plate flow chamber capable of applying electric and shearing force stimulation, which is formed by superposing three plates and two gaskets, wherein an upper plate (2) is provided with a fluid inlet/outlet port; an upper gasket (3) is provided with a diversion trench (4); a middle plate (5) is provided with a rectangular slit (6); a lower gasket (10) is provided with a flow cavity (18); the middle plate (5) above the flow cavity (18) is provided with a plate electrode (7); a lower plate (11) below the flow cavity (18) is provided with a plate electrode (16); a pair of electrodes (14 and 17) are respectively arranged on four sides of the flow cavity (18); and the plate electrode (16) is composed of a sheet (22), a PDMS (polydimethylsiloxane) film (23) and a graphene film (24), and has a microtopological structure on the surface. When applying electric and shearing force stimulation with different modes and intensities, the invention implements microtopological structure regulation on the cell (19). The structure of the device is simple, compact and reliable.

The invention relates to application of 3, 4-dihydro-2H-benzo-[1, 4] oxazine or salt of the oxazine in preparing drugs for inhibiting iron death, especially to application of 3, 4-dihydro-2H-benzo-[1,4] oxazine compounds or salt of the oxazine in preparing drugs for treating diseases associated with iron death, and the diseases associated with iron death include brain trauma, stroke, cardiovascular diseases, liver and kidney failure, inflammation and neurodegenerative diseases such as Parkinson's disease and schizophrenia.

The invention relates to a cheap catalyst for simultaneous denitration and demercuration on smoke gas as well as a preparation method and application thereof, belongs to the technical field of atmospheric pollution control, and particularly relates to a vanadium-free waste reutilization catalyst as well as a preparation method and application thereof. The catalyst comprises carrier red mud and metal oxide parts for modifying the red mud, wherein metal oxides are one or several kinds of materials in manganese and cobalt. The catalyst aims at the problems of high cost and toxicity of the existing catalyst for simultaneous denitration and demercuration. The catalyst provided by the invention uses aluminum making industry waste-red mud as catalyst carriers; the acidification dealkalization treatment is performed; the specific surface area and the porosity of the carrier are obviously improved. The catalyst subjected to manganese or cobalt modification is used for simultaneously performingdenitration and demercuration on the smoke gas which does not contain HCL; the application temperature is higher than 180 DEG C; the air speed is 50,000 to 100,000 h<-1>; the efficient removal can berealized on nitric oxides and elemental mercury in the smoke gas.

The invention discloses a Chinese medicinal composition for preventing and treating Mycoplasma gallisepticum and a preparation method thereof. The Chinese medicinal composition is prepared from the following raw material medicaments in part by weight: 1 to 4 parts of baical skullcap root, 1 to 4 parts of honeysuckle, 1 to 4 parts of tatarian aster root, 1 to 4 parts of ephedra herb, 0.2 to 1.5 parts of tangerine peel and 0.2 to 1.5 parts of liquoric root. The Chinese medicinal composition has the effects of clearing heat and releasing toxin, moistening the lung to stop cough, relieving cough and removing asthma, eliminating inflammation and relieving pain, improving immunity and the like, has simple preparation process, low cost, no toxic or side effect, and is not easy to generate medicament resistance. Various active components in the oral liquid of the Chinese medicinal composition are dispersed in a medium in a molecule or microparticle state, have high dispersity, are quickly absorbed, and can quickly begin to work. Clinical pharmacodynamic experiment results show that the Chinese medicinal composition has good treatment effect on chronic respiratory disease and the like caused by the Mycoplasma gallisepticum infection, and can also improve the weight increment of chickens and fodder returns.

The invention belongs to the technical field of composite scaffolds and discloses a composite scaffold for improving gaps and pores to promote the cell adhesion rate and a preparation method. A channel pore and a spherical pore of the composite scaffold are 150mum-650mum and 3mum-15mum respectively; the preparation method comprises the following steps: obtaining a CS/HA (chitosan/hydroxyapatite) scaffold with pores and spherical pores by adopting an in situ hybridization technology and a freeze-drying method; connecting CS and RGD (arginine-glycin-aspartate) peptides with hydrogen bonds, and modifying the RGD (arginine-glycin-aspartate) peptides on the surface of a porous channel of the CS/HA scaffold with a static self-assembly method, so as to prepare a three-dimensional porous CS/HA scaffold with efficient adherent cells containing the RGD peptides. The scaffold has better cytocompatibility; through composition with RGD, the functions of attraction, induction and growth control of the three-dimensional porous CS/HA scaffold on cells are obviously enhanced; a physical absorption method and a chemical fixation method are combined in the preparation method, so that the material hasbetter adsorbability and stability.

The invention provides the novel route of administration and preparing process for Chinese medicinal injection for treating nervous prostration, loss of appetite, undernourishment, coronary disease, angina pectoris and arrhythmia. The injection is prepared from sika deer horns as the raw material, and can be made into the dosage forms of concentrated solution for injection, freeze-dried powder, germ-free powder, 5% glucose injection, and 9% sodium chloride injection.

The invention relates to a preparation method of a thin-layer two-dimensional material, which comprises the following steps: 1) dropwise adding a first solvent on a substrate to obtain a first solvent layer; 2) adhering the two-dimensional material by using an adhesive tape, and adhering the adhesive tape adhered with the two-dimensional material to the substrate containing the first solvent layer, so that the two-dimensional material is in contact with the first solvent layer; 3) injecting a second solvent below the adhesive tape; 4) performing heat treatment; and 5) stripping the adhesive tape to obtain the thin-layer two-dimensional material adhered to the substrate. Compared with the prior art, the thin-layer two-dimensional material prepared by the method has the advantages of large area, thin thickness, high yield, simple operation process, no need of large-scale film preparation equipment, and no obvious toxicity since auxiliary materials involved in the process are common solvents in laboratories. Compared with a traditional solvent stripping method, the method has the advantages that the probability of obtaining few-layer even single-layer two-dimensional materials is obviously improved, and the quality of the prepared materials is improved.

The invention provides application of a selenium preparation in preparation of a medicine for treating Crohn disease. In-vitro cell experiment research proves that the sodium selenite has a good effect of inhibiting Th1 differentiation when the concentration of the sodium selenite is controlled to be 0.5-1 mu M, and has no obvious toxicity to cells. The sodium selenite has a remarkable improvement effect on enteritis symptoms induced by adoptive transfer of mouse T cells, Th1 cells in mouse colon tissue can be remarkably inhibited, and small-range clinical tests show that the sodium selenite can promote relieving of enteritis of patients with selenium-deficient Crohn disease. The invention provides new application of sodium selenite, which is of great significance to research and development of medicines for treating Crohn disease and can provide reference for development and mechanism research of clinical medicines.

The invention relates to the field of medicinal chemistry, and specifically relates 3-hydroxy-3-[2,3-dihydroquinoline-4-keto-3-yl]indole-2-ketone compounds (I) and pharmaceutically acceptable salts thereof or pharmaceutically acceptable solvent mixtures thereof, a preparation method thereof, and uses of the compounds in preparing medicaments for preventing or treating diseases related to abnormal cell proliferation, morphologic change and the like, in particular medicaments for preventing or treating tumor growth and transfer.

The invention discloses a tricyclic diterpenoid derivative as shown in a formula (I) and a preparation method of the tricyclic diterpenoid derivative. A series of novel tricyclic diterpenoid derivatives as shown in the formula (I) can be prepared by taking the tricyclic diterpenoid derivative as shown in a formula (5) as a leading compound through such reactions as esterification, amidation, protection, acylation and deprotection. Furthermore, the invention also provides an application of the tricyclic diterpenoid derivative in preparation of neuroprotective drugs.

The invention discloses an application of D609 in preparation of a medicine for preventing and treating retinal injury diseases. The Chinese name of D609 is tricyclic decane-9-yl-dithiocarbonate potassium salt, and the D609 is an antiviral and antitumor small molecular compound, which belongs to a selective inhibitor of phosphatidylcholine specific phospholipase (PC-PLC). According to the invention, the wide and deep research is carried out, the unexpected discovery is realized for the first time, the expression of metallothionein is up-regulated by the D609; the oxidative damage of RPE cellscan be effectively inhibited; therefore, the compound can be used for preventing or treating retinal injury diseases caused by oxidative stress injury of retinal pigment epithelial cells, especially,the compound can be extremely effectively used for preventing or treating macular degeneration diseases of retina, has no obvious drug toxicity, can effectively control the occurrence and developmentof injury diseases of retina, and provides a new theoretical support for developing unknown biological activity of D609 and future clinical treatment effects.

The present invention relates to applications of 8-hydroxyquinoline (8-OH-quinoline) compounds or salts thereof in preparation of drugs for treatment of diseases associated with BRD4, wherein the diseases associated with BRD4 comprise NUT-midline carcinoma, acute lymphatic leukemia, mixed lineage leukemia, multiple myeloma, Burkitt's lymphoma, hepatocellular carcinoma, triple negative breast cancer, non-small cell lung cancer, prostate cancer, pancreatic cancer, neuroblastoma and other tumor types, and heart failures such as cardiac hypertrophy and cardiomyocyte hypertrophy.